+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical effect and positioning of capecitabine for metastatic breast carcinoma



Clinical effect and positioning of capecitabine for metastatic breast carcinoma



Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(8): 1315-1318



We evaluated the effect of capecitabine for metastatic breast carcinoma. Of 18 metastatic breast carcinoma patients experienced in our institution from November 2002 to July 2007, all patients had resisted the anthracycline or taxanes therapy before. Of these patients, 7 had liver, 6 had bone, and 5 had lung metastases. The capecitabine response in these 18 patients was evaluated as follows: PR in 4, long SD in 6, SD in 3, and PD in 5. In particular, 3 patients with liver metastases showed remarkable tumor regression. Compared to the 3rd-and 4th-line, 2nd-line capecitabine proved more effective. Hand-foot syndrome was found in 4 patients. Only one patient discontinued the therapy due to nausea. These results showed that capecitabine may be a useful treatment regimen for chemotherapy-resistant metastatic breast carcinoma patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052114580

Download citation: RISBibTeXText

PMID: 18701841


Related references

More effective positioning of capecitabine for advanced and metastatic breast cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(4): 649-653, 2010

Effect of lapatinib plus capecitabine (L+C) on quality of life (QOL) compared to capecitabine (C) alone in ErbB2+ metastatic breast cancer (MBC): An exploratory analysis. Journal of Clinical Oncology 26(15_suppl): 9532-9532, 2016

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. Cancer ChemoTherapy and Pharmacology 68(6): 1413-1419, 2012

Gemcitabine in combination with capecitabine in metastatic breast carcinoma: A phase I-II study. Journal of Clinical Oncology 23(16_suppl): 870-870, 2016

Clinical experience of capecitabine in metastatic breast cancer. European Journal of Cancer 38(Supplement 2): S10-S14, February, 2002

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer. Journal of Oncology 2012: 862921, 2012

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92(7): 1759-1768, October 1, 2001

Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncology Letters 10(4): 2598-2602, 2015

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Research and Treatment 117(3): 577-589, 2009

Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients. Journal of B.U.On. 18(4): 831-837, 2014

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. Oncology Letters 9(2): 987-993, 2015

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical Oncology 23(4): 792-799, 2005

Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer. Future Oncology 6(2): 201-207, 2010

Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer. Journal of Clinical Oncology 24(18_suppl): 10727-10727, 2016